Cancers, Vol. 11, Pages 1071: Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies

Cancers, Vol. 11, Pages 1071: Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies Cancers doi: 10.3390/cancers11081071 Authors: Theodoros P. Vassilakopoulos Chrysovalantou Chatzidimitriou John V. Asimakopoulos Maria Arapaki Evangelos Tzoras Maria K. Angelopoulou Kostas Konstantopoulos Although classical Hodgkin lymphoma (cHL) is usually curable, 20–30% of the patients experience treatment failure and most of them are typically treated with salvage chemotherapy and autologous stem cell transplantation (autoSCT). However, 45–55% of that subset further relapse or progress despite intensive treatment. At the advanced stage of the disease course, recently developed immunotherapeutic approaches have provided very promising results with prolonged remissions or disease stabilization in many patients. Brentuximab vedotin (BV) has been approved for patients with relapsed/refractory cHL (rr-cHL) who have failed autoSCT, as a consolidation after autoSCT in high-risk patients, as well as for patients who are ineligible for autoSCT or multiagent chemotherapy who have failed ≥ two treatment lines. However, except of the consolidation setting, 90–95% of the patients will progress and require further treatment. In this clinical setting, immune checkpoint inhibitors (CPIs) have produced impressive results. Both nivolumab and pembrolizumab have been approved for rr-cHL after autoSCT and BV failure, whil...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research